Iprasol Respirator Solution (2.5 mg + 500 mcg)/ml is a combination bronchodilator formulated for inhalation via nebulizer. It contains Salbutamol, a short-acting beta₂-adrenergic agonist, and Ipratropium Bromide, an anticholinergic bronchodilator. This dual-acting formulation provides effective relief from bronchospasm by targeting two different mechanisms involved in airway narrowing. Iprasol Respirator Solution is commonly used in the management of chronic obstructive pulmonary disease (COPD) and bronchial asthma, especially in patients who require nebulized therapy for optimal drug delivery.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Combined Bronchodilators
Beta₂-Agonist and Anticholinergic Agents

Composition

Each ml of respirator solution contains:

• Salbutamol 2.5 mg

• Ipratropium Bromide 500 mcg

Indications

Iprasol Respirator Solution (2.5 mg + 500 mcg)/ml is indicated for:

• Treatment and prevention of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema

• Adjunctive therapy in bronchial asthma

• Acute and chronic obstructive airway conditions where combination bronchodilator therapy is required

It is particularly beneficial for patients who do not respond adequately to single bronchodilator therapy.

Pharmacology

Salbutamol acts by selectively stimulating beta₂-adrenergic receptors in bronchial smooth muscle, leading to rapid relaxation of the airways and improved airflow. Ipratropium Bromide blocks muscarinic receptors in the bronchial tree, inhibiting acetylcholine-mediated bronchoconstriction. When used together, these agents provide complementary and enhanced bronchodilation, improving lung function and reducing respiratory symptoms. Both components primarily act locally in the lungs, which helps minimize systemic absorption and reduces the risk of systemic side effects.

Dosage and Administration

The dosage of Iprasol Respirator Solution should be individualized according to the patient’s age, clinical condition, and response to therapy.

• Administered by inhalation using a suitable nebulizer

• The prescribed volume may be used directly or diluted with normal saline as advised by a healthcare professional

• Nebulization should be performed under medical supervision, particularly in children and elderly patients

Proper nebulizer technique is essential to ensure effective drug delivery.

Contraindications

Iprasol Respirator Solution is contraindicated in patients with:

• Known hypersensitivity to salbutamol, ipratropium bromide, atropine, or any component of the formulation

• History of allergic reactions to similar bronchodilator medicines

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Use with caution in patients with cardiovascular disease, hypertension, diabetes mellitus, or hyperthyroidism

• Caution is advised in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention

• Avoid contact of nebulized mist with the eyes

• Not intended as the sole therapy for severe acute asthma unless directed by a physician

Adverse Effects

Iprasol Respirator Solution is generally well tolerated. Possible adverse effects include:

• Tremor

• Dry mouth

• Headache

• Palpitations

• Cough or throat irritation

These effects are usually mild and transient.

Drug Interactions

Caution is advised when used with:

• Other beta-agonists or anticholinergic agents

• Beta-blockers

• Diuretics and corticosteroids, which may increase the risk of hypokalemia

Storage

Store in a cool and dry place, protected from light. Do not freeze. Keep out of reach of children.

Conclusion

Iprasol Respirator Solution (2.5 mg + 500 mcg)/ml offers effective dual bronchodilation through the combined action of salbutamol and ipratropium bromide. Its nebulized formulation ensures efficient delivery to the lungs, making it a valuable option for the management of COPD and asthma-related bronchospasm.